NLS Pharmaceutics AG
NLSPNASDAQHealthcare
$2.91
$-0.42(-12.61%)
Market Cap$919601
P/E Ratio—
52W High$43.4
52W Low$0.76
NLS Pharmaceutics AG (NLSP) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
NLSP · earnings · updated Jun 8, 2026
Latest Earnings
Q4 FY2025Report Date: Oct 6, 2025EPS Actual
-$5.54
Revenue
—
Fiscal Period
Q4 FY2025
FY ends December
Report Date
Oct 6, 2025
After Market Close
🔥 5-Quarter EPS Beat Streak
NLSP reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| — Q4 FY2025 | Oct 6, 2025 | — | -$5.54 | — | — | — | — |
| ◌ Q2 FY2025 | May 16, 2025 | — | — | — | — | — | — |
| ◌ Q4 FY2024 | Oct 18, 2024 | — | — | — | — | — | — |
| ▲ Q2 FY2024 | May 15, 2024 | -$8.40 | -$0.00 | +100.0% | — | — | — |
| ▲ Q2 FY2023 | Jun 30, 2023 | -$6.80 | -$0.20 | +97.1% | — | — | — |
| ▲ Q2 FY2023 | May 5, 2023 | -$12.00 | -$0.29 | +97.5% | — | — | — |
| — Q4 FY2022 | Oct 11, 2022 | — | -$0.54 | — | — | — | — |
| ▲ Q1 FY2022 | Mar 24, 2022 | -$13.80 | -$0.50 | +96.4% | — | — | — |
Q4 FY2025
Oct 6, 2025
EPS Actual
-$5.54
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2025
May 16, 2025
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2024
Oct 18, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2024
May 15, 2024Beat
EPS Actual
-$0.00
EPS Est.
-$8.40
EPS Surpr.
+100.0%
Revenue
—
Q2 FY2023
Jun 30, 2023Beat
EPS Actual
-$0.20
EPS Est.
-$6.80
EPS Surpr.
+97.1%
Revenue
—
Q2 FY2023
May 5, 2023Beat
EPS Actual
-$0.29
EPS Est.
-$12.00
EPS Surpr.
+97.5%
Revenue
—
Q4 FY2022
Oct 11, 2022
EPS Actual
-$0.54
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2022
Mar 24, 2022Beat
EPS Actual
-$0.50
EPS Est.
-$13.80
EPS Surpr.
+96.4%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2024 | $1.54 | $1.54 | $1.54 | 1 |
| Q2 FY2024 | $1.34 | $1.34 | $1.34 | 1 |
| Q1 FY2024 | $1.58 | $1.58 | $1.58 | 1 |
| Q4 FY2023 | $2.09 | $2.09 | $2.09 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2023 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q4 FY2025 | Oct 6, 2025 | — | $20.00 | $19.20 | -4.00% |
| ▲ Q2 FY2024 | May 15, 2024 | +100.0% | $60.40 | $58.40 | -3.31% |
| ▲ Q2 FY2023 | Jun 30, 2023 | +97.1% | $368.00 | $440.00 | +19.57% |
| ▲ Q2 FY2023 | May 5, 2023 | +97.5% | $508.20 | $552.00 | +8.62% |
| — Q4 FY2022 | Oct 11, 2022 | — | $201.30 | $190.00 | -5.61% |
| ▲ Q1 FY2022 | Mar 24, 2022 | +96.4% | $547.40 | $576.10 | +5.24% |
| — Q3 FY2021 | Sep 28, 2021 | — | $1,020.00 | $988.00 | -3.14% |
| ▲ Q2 FY2021 | May 14, 2021 | +95.0% | $1,280.00 | $1,344.00 | +5.00% |
Q4 FY2025-4.00%
Report Date
Oct 6, 2025
EPS Beat/Miss
—
Price Before
$20.00
Price After
$19.20
Q2 FY2024-3.31%
Report Date
May 15, 2024
EPS Beat/Miss
+100.0%
Price Before
$60.40
Price After
$58.40
Q2 FY2023+19.57%
Report Date
Jun 30, 2023
EPS Beat/Miss
+97.1%
Price Before
$368.00
Price After
$440.00
Q2 FY2023+8.62%
Report Date
May 5, 2023
EPS Beat/Miss
+97.5%
Price Before
$508.20
Price After
$552.00
Q4 FY2022-5.61%
Report Date
Oct 11, 2022
EPS Beat/Miss
—
Price Before
$201.30
Price After
$190.00
Q1 FY2022+5.24%
Report Date
Mar 24, 2022
EPS Beat/Miss
+96.4%
Price Before
$547.40
Price After
$576.10
Q3 FY2021-3.14%
Report Date
Sep 28, 2021
EPS Beat/Miss
—
Price Before
$1,020.00
Price After
$988.00
Q2 FY2021+5.00%
Report Date
May 14, 2021
EPS Beat/Miss
+95.0%
Price Before
$1,280.00
Price After
$1,344.00
Avg Beat Reaction+7.02%
Beat Rate5 / 8 quarters
Largest Move+19.57% (Q2 FY2023)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: NLSP ends December
NLS Pharmaceutics AG (NLSP) most recently reported earnings on October 6, 2025 for Q4 FY2025, posting EPS of $-5.54 (in line with the analyst consensus of —). NLSP has beaten EPS estimates for 5 consecutive quarters. The next NLSP earnings date is expected around September 1, 2026.
Each quarter, investors track NLSP earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. NLSP revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
NLSP's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
NLSP earnings · 4 questionsNLS Pharmaceutics AG's next earnings report is expected around September 1, 2026. NLSP typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; NLSP historically reports after market close (AMC).
NLSP earnings datewhen is NLSP earningsNLSP next earnings datewhen does NLSP report earningsNLSP earnings calendar
▸ Source: FMP · NLS Pharmaceutics AG SEC filings · US GAAP · NLS Pharmaceutics AG SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026